NCT03250117View on ClinicalTrials.gov

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

May 22, 2018

Study Completion Date

May 22, 2018

Conditions
Parkinson Disease
Interventions
DRUG

Ropinirole oral product

oral immediate-release ropinirole

DRUG

Ropinirole Implant

ropinirole hydrochloride/ethylene vinyl acetate

Trial Locations (3)

32806

Orlando, Florida, Orlando

48334

Farmington Hills, Michigan, Farmington Hills

98034

Kirkland, Washington, Kirkland

Sponsors
All Listed Sponsors
lead

Titan Pharmaceuticals

INDUSTRY

NCT03250117 - Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole | Biotech Hunter | Biotech Hunter